drugset / Trial / NCT00002442

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

NCT00002442

Phase 2 Completed Glaxo Wellcome
Open-labelTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of 2 dosing schedules (once daily vs twice daily) of lamivudine (3TC) given with stavudine (d4T) and either indinavir (IDV) or nelfinavir (NFV) for 24 weeks.

Timeline

Start
1999-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 150 mg
Subject Lamivudine Other / unclassified 300 mg
Background INDINAVIR ANHYDROUS Other / unclassified
Background Nelfinavir Other / unclassified
Background Stavudine Other / unclassified